Foretinib
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Foretinib is an experimental drug candidate for the treatment of cancer. It was discovered by Exelixis and is under development by GlaxoSmithKline. About 10 Phase II clinical trials have been run. it appears development has been discontinued. Foretinib is an inhibitor of the kinase enzymes c-Met and vascular endothelial growth factor receptor 2 (VEGFR-2).
Foretinib is an experimental drug candidate for the treatment of cancer. It was discovered by Exelixis and is under development by GlaxoSmithKline. About 10 Phase II clinical trials have been run. it appears development has been discontinued. Foretinib is an inhibitor of the kinase enzymes c-Met and vascular endothelial growth factor receptor 2 (VEGFR-2).
See also
c-Met inhibitors Cabozantinib, a similar molecule and kinase inhibitor with FDA approval VEGFR inhibitor tyrosine-kinase inhibitor
References
Text derived from https://en.wikipedia.org/w/index.php?oldid=1330279606 under CC BY-SA 4.0; modifications have been made.